ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

What's Up With These Ridiculous Stock Gains?

Steve Reitmeister didn't want me to tell you this. He felt that one strategy's performance stands out so much that... Read on >>

Quote:

Search for Ticker

Free Membership

Search:

NEXM: Nexmed Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

NEXMED INC (NASD)
NEXM	0.26	0.06	(N/A%)	Vol. 49,647,298	16:00 ET

NexMed, Inc. is a pharmaceutical and medical technology company. They develop and commercialize therapeutic products based on proprietary delivery systems. They are currently focusing their efforts on new and patented pharmaceutical products based on a penetration enhancement topical delivery technology known as NexACT(R), which may enable an active drug to be better absorbed through the skin.

General Information

NEXMED INC

89 Twin Rivers Drive East Windsor, NJ 08520 Phone: 609 371-8123 Fax: 609 426-9116 Web: www.nexmed.com Email: pschwartz@rxir.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	N/A

Price and Volume Information

Zacks Rank
Yesterday's Close	0.20
52 Week High	0.54
52 Week Low	0.05
Beta	1.22
20 Day Moving Average	1,054,976.13
Target Price Consensus	N/A

% Price Change
4 Week	7.19
12 Week	-12.82
YTD	21.43

% Price Change Relative to S&P 500
4 Week	6.03
12 Week	-17.81
YTD	0.50

Share Information
Shares Outstanding (millions)	88.99
Market Capitalization (millions)	15.13
Short Ratio	0.01
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	N/A
Current Year EPS Consensus Estimate	N/A
Estimated Long-Term EPS Growth Rate	N/A
Next EPS Report Date	N/A

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	N/A
30 Days Ago	N/A
60 Days Ago	N/A
90 Days Ago	N/A

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	-200.00%
vs. Previous Quarter	-300.00%

Sales Growth
vs. Previous Year	-64.05%
vs. Previous Quarter:	6.80%

Price Ratios
Price/Book	9.28
Price/Cash Flow	-
Price / Sales	2.45

ROE
09/30/09	-42.76
06/30/09	-179.05
03/31/09	23.95

ROA
09/30/09	-9.75
06/30/09	-30.92
03/31/09	4.53

Current Ratio
09/30/09	3.67
06/30/09	2.90
03/31/09	4.22

Quick Ratio
09/30/09	3.67
06/30/09	2.90
03/31/09	4.22

Operating Margin
09/30/09	-12.80
06/30/09	-41.42
03/31/09	5.55

Net Margin
09/30/09	-27.99
06/30/09	-56.15
03/31/09	-50.58

Pre-Tax Margin
09/30/09	-27.99
06/30/09	-56.15
03/31/09	-50.58

Book Value
09/30/09	0.02
06/30/09	0.02
03/31/09	0.03

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	2.20
06/30/09	2.55
03/31/09	1.85

Debt to Capital
09/30/09	68.77
06/30/09	71.85
03/31/09	64.87


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research